A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Nirsevimab (BEYFORTUS)

Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2023-07-18
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Nirsevimab used for?

Nirsevimab is a Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody medication tracked in Medicare Part D.

Is there a generic for Nirsevimab?

No. Nirsevimab is brand-only with no generic equivalents currently in market.

How much does my plan pay for Nirsevimab?

NADAC pricing data not currently available for this drug.

Is Nirsevimab on the FDA shortage list?

No. Nirsevimab is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody2 alternatives in D1
01
Clesrovimab
Brand: ENFLONSIA
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Palivizumab
Brand: Synagis
Lowest NADAC
0Generic mfrs
$42,485CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.